1-4 of 4
Sheila Breslin
Close
Sort by
Journal Articles

Results of a Prospective Phase II Trial of Limited and Extended Rituximab Treatment in Nodular Lymphocyte Predominant Hodgkin’s Disease (NLPHD).

Sandra J. Horning, MD, Nancy L. Bartlett, MD, Sheila Breslin, RN, Ranjana H. Advani, MD, Richard T. Hoppe, MD, Bradley C. Ekstrand, MD, Jennifer B. Lucas, MD
Journal: Blood
Blood (2007) 110 (11): 644.
https://doi.org/10.1182/blood.V110.11.644.644
Published: 2007
Journal Articles

Assessment of Favorable (F) Versus Unfavorable (U) Early Stage Hodgkin’s Disease (HD); the Stanford V + Radiotherapy (RT) Experience.

Ranjana Advani, MD, Lauren Maeda, Richard T. Hoppe, MD, Sheila Breslin, RN, Saul A. Rosenberg, MD, David Baer, MD, Joseph Mason, MD, Sandra J. Horning, MD
Journal: Blood
Blood (2005) 106 (11): 1932.
https://doi.org/10.1182/blood.V106.11.1932.1932
Published: 2005
Journal Articles

Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma

Clinical Trials & Observations
Steven M. Horwitz, Robert S. Negrin, Karl G. Blume, Sheila Breslin, Monic J. Stuart, Keith E. Stockerl-Goldstein, Laura J. Johnston, Ruby M. Wong, Judith A. Shizuru, Sandra J. Horning
Journal: Blood
Blood (2004) 103 (3): 777–783.
https://doi.org/10.1182/blood-2003-04-1257
Published: 2004
Journal Articles

Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial

Clinical Trials & Observations
Bradley C. Ekstrand, Jennifer B. Lucas, Steven M. Horwitz, Zhen Fan, Sheila Breslin, Richard T. Hoppe, Yasodha Natkunam, Nancy L. Bartlett, Sandra J. Horning
Journal: Blood
Blood (2003) 101 (11): 4285–4289.
https://doi.org/10.1182/blood-2002-08-2644
Published: 2003